A post-hoc pooled analysis to evaluate efficacy and safety of insulin glargine 300 U/mL in insulin-naïve people with type 2 diabetes with/ without prior use of glucagon-like peptide-1 receptor agonist therapy
Por:
Cheng, AYY, Mauricio, D, Ritzel, R, Al-Sofiani, ME, Bailey, T, Mabunay, MA, Bonnemaire, M, Melas-Melt, L, Mimouni, S, Davies, M
Publicada:
1 nov 2024
Ahead of Print:
1 oct 2024
Resumen:
Aims: To evaluate treatment advancement with insulin glargine 300 U/mL (Gla-300), with or without prior glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy in type 2 diabetes (T2D). Methods: Efficacy and safety outcomes of insulin-na & iuml;ve patients intensifying with Gla-300, with/without prior GLP-1 RA therapy, were evaluated in three analyses (N = 3562): a pooled analysis of seven interventional studies, a subanalysis comparing participants who stopped GLP-1 RA therapy and initiated Gla-300 with those who received add-on Gla-300, and an expanded analysis including two observational studies. Results: Glycaemic outcomes, including HbA1c improvement and fasting plasma glucose, were similar between groups with/without prior GLP-1 RA use. HbA1c least squares mean change from baseline was - 1.7 % and 1.6 % with and without prior GLP-1 RA, respectively. Glycaemic outcomes were similar between participants who stopped GLP-1 RA therapy when initiating Gla-300 and those who received add-on Gla-300, although more participants receiving add-on Gla-300 achieved HbA1c targets. The expanded analysis yielded similar results. Incidence of hypoglycaemia was low with no clinically relevant weight changes in all analyses. Conclusions: Treatment advancement with Gla-300 in patients with T2D, with/without prior GLP-1 RA therapy, improved glycaemic outcomes with no relevant impact on weight, while maintaining a low hypoglycaemia risk.
Filiaciones:
Cheng, AYY:
Univ Toronto, Dept Med, Toronto, ON, Canada
Trilium Hlth Partners & Unity Hlth, Toronto, ON, Canada
Mauricio, D:
Hosp Univ Santa Creu i St Pau, CIBERDEM, Dept Endocrinol & Nutr, Barcelona, Spain
Ritzel, R:
Stadt Klinikum Munchen GmbH, Klinikum Schwabing, Div Endocrinol Diabet & Angiol, Munich, Germany
Stadt Klinikum Munchen GmbH, Klinikum Bogenhausen, Munich, Germany
Al-Sofiani, ME:
King Saud Univ, Coll Med, Dept Internal Med, Div Endocrinol, Riyadh, Saudi Arabia
Johns Hopkins Univ, Div Endocrinol Diabet & Metab, Baltimore, MD USA
Bailey, T:
AMCR Inst, Escondido, CA USA
Mabunay, MA:
Sanofi, Global Med, Singapore, Singapore
Bonnemaire, M:
Sanofi, Paris, France
Melas-Melt, L:
Ividata Life Sci, Levallois Perret, France
Mimouni, S:
Univ Algiers, Pierre & Marie Curie Ctr, Algiers, Algeria
Davies, M:
Univ Leicester, Diabet Res Ctr, Leicester, England
NIHR Leicester Biomed Res Ctr, Leicester, England
hybrid
|